<DOC>
	<DOC>NCT01662063</DOC>
	<brief_summary>This open-label extension study will evaluate the long-term safety and efficacy of SC TCZ in participants with moderate to severe RA who have completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core studies on SC or intravenous (IV) TCZ. Participants will receive TCZ 162 milligrams (mg) SC every week (QW) or every 2 weeks (Q2W) for up to 96 weeks.</brief_summary>
	<brief_title>A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Completed the 97week WA22762 (NCT01194414) or 96week NA25220 (NCT01232569) core study on SC or IV TCZ and, based on the Investigator's judgment, may continue to benefit from TCZ treatment in this study investigating the SC formulation Receiving treatment on an outpatient basis Females of childbearing potential and males with female partners of childbearing potential must agree to use reliable means of contraception as defined by protocol Premature withdrawal from WA22762 (NCT01194414) or NA25220 (NCT01232569) core studies for any reason History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies Evidence of serious uncontrolled concomitant disease or disorder Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of Screening or oral antibiotics within 2 weeks of Screening History of or currently active primary or secondary immunodeficiency Oral corticosteroids at greater than (&gt;) 10 mg per day prednisone or equivalent, or nonsteroidal antiinflammatory drugs (NSAIDs) above the maximum recommended dose Intraarticular or parenteral corticosteroids within 4 weeks prior to Baseline Treatment with any investigational or commercially available biologic diseasemodifying antirheumatic drug (DMARD) other than TCZ at any time between completion of the core study WA22762 (NCT01194414) or NA25220 (NCT01232569) and enrollment in the longterm extension study Pregnant or breastfeeding women History of alcohol, drug, or chemical abuse within 1 year prior to Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>